Search Results - "PERRY, Kenneth W"

The Discovery of Fluoxetine Hydrochloride (Prozac) by Wong, David T, Perry, Kenneth W, Bymaster, Frank P

“…In the early 1970s, evidence of the role of serotonin (5-hydroxytryptamine or 5-HT) in depression began to emerge and the hypothesis that enhancing 5-HT…”
Get full text

Effect of the attention deficit/hyperactivity disorder drug atomoxetine on extracellular concentrations of norepinephrine and dopamine in several brain regions of the rat by Swanson, Chad J., Perry, Kenneth W., Koch-Krueger, Susanne, Katner, Jason, Svensson, Kjell A., Bymaster, Frank P.

“…Atomoxetine is a selective inhibitor of norepinephrine transporters and is currently being used in the pharmacotherapy of attention deficit/hyperactivity…”
Get full text

In vivo pharmacological characterization of the structurally novel, potent, selective mGlu2/3 receptor agonist LY404039 in animal models of psychiatric disorders by RORICK-KEHN, Linda M, JOHNSON, Bryan G, SCHOEPP, Darryle D, KNITOWSKI, Karen M, SALHOFF, Craig R, WITKIN, Jeffrey M, PERRY, Kenneth W, GRIFFEY, Kelly I, TIZZANO, Joseph P, MONN, James A, MCKINZIE, David L

“…Data from both preclinical and clinical studies have provided proof of concept that modulation of limbic and forebrain glutamate, via mGlu2/3 receptor…”
Get full text

Glutamatergic regulation of brain histamine neurons: In vivo microdialysis and electrophysiology studies in the rat by Fell, Matthew J., Flik, Gunnar, Dijkman, Ulrike, Folgering, Joost H.A., Perry, Kenneth W., Johnson, Bryan J., Westerink, Ben H.C., Svensson, Kjell A.

“…The interactions between the glutamatergic and the histaminergic systems in the brain are not fully understood. Here we studied histamine release in the medial…”
Get full text

The CB1 receptor antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: implications for therapeutic actions by Tzavara, Eleni T, Davis, Richard J, Perry, Kenneth W, Li, Xia, Salhoff, Craig, Bymaster, Frank P, Witkin, Jeffrey M, Nomikos, George G

“…In order to explore potential therapeutic implications of cannabinoid antagonists, the effects of the prototypical cannabinoid antagonist SR141716A on…”
Get full text

Neurochemical and behavioral profiling of the selective GlyT1 inhibitors ALX5407 and LY2365109 indicate a preferential action in caudal vs. cortical brain areas by Perry, Kenneth W., Falcone, Julie F., Fell, Matthew J., Ryder, John W., Yu, Hong, Love, Patrick L., Katner, Jason, Gordon, Kimberly D., Wade, Mark R., Man, Teresa, Nomikos, George G., Phebus, Lee A., Cauvin, Annick J., Johnson, Kirk W., Jones, Carrie K., Hoffmann, Beth J., Sandusky, George E., Walter, Magnus W., Porter, Warren J., Yang, Lijuan, Merchant, Kalpana M., Shannon, Harlan E., Svensson, Kjell A.

“…Selective inhibitors of the glycine transporter 1 (GlyT1) have been implicated in central nervous system disorders related to hypoglutamatergic function such…”
Get full text

In vitro and in vivo evidence for a lack of interaction with dopamine D2 receptors by the metabotropic glutamate 2/3 receptor agonists 1S,2S,5R,6S-2-aminobicyclo[3.1.0]hexane-2,6-bicaroxylate monohydrate (LY354740) and (-)-2-oxa-4-aminobicyclo[3.1.0] Hexane-4,6-dicarboxylic acid (LY379268) by Fell, Matthew J, Perry, Kenneth W, Falcone, Julie F, Johnson, Bryan G, Barth, Vanessa N, Rash, Karen S, Lucaites, Virginia L, Threlkeld, Penny G, Monn, James A, McKinzie, David L, Marek, Gerard J, Svensson, Kjell A, Nelson, David L

“…Some recently published in vitro studies with two metabotropic glutamate 2/3 receptor (mGluR(2/3)) agonists [(-)-2-oxa-4-aminobicyclo[3.1.0]…”
Get more information

Activation of metabotropic glutamate (mGlu)2 receptors suppresses histamine release in limbic brain regions following acute ketamine challenge by Fell, Matthew J., Katner, Jason S., Johnson, Bryan G., Khilevich, Albert, Schkeryantz, Jeffrey M., Perry, Kenneth W., Svensson, Kjell A.

“…In the present study we demonstrated that ketamine, an NMDA antagonist and possible psychotomimetic, increases extracellular histamine (HA) in the rat brain…”
Get full text

Vasopressin/Serotonin Interactions in the Anterior Hypothalamus Control Aggressive Behavior in Golden Hamsters by Ferris, Craig F, Melloni Jr, Richard H, Koppel, Gary, Perry, Kenneth W, Fuller, Ray W, Delville, Yvon

“…Studies in several species of rodents show that arginine vasopressin (AVP) acting through a V1A receptor facilitates offensive aggression, i.e., the initiation…”
Get full text

Influence of fluoxetine on the ability of bupropion to modulate extracellular dopamine and norepinephrine concentrations in three mesocorticolimbic areas of rats by Li, Simon Xi-Ming, Perry, Kenneth W, Wong, David T

“…The finding that serotonin (5-HT) can modulate dopamine (DA) and norepinephrine (NE) release in the brain has led us to hypothesize that fluoxetine, a…”
Get full text

Modulation of neurotransmitter release in orexin/hypocretin-2 receptor knockout mice: A microdialysis study by Ortega, Jorge E., Katner, Jason, Davis, Richard, Wade, Mark, Nisenbaum, Laura, Nomikos, George G., Svensson, Kjell A., Perry, Kenneth W.

“…Orexinergic neurons are discretely localized within the lateral hypothalamus and have widespread projections to the whole brain. Here, the role of…”
Get full text

Brain region and dose effects of an olanzapine/fluoxetine combination on extracellular monoamine concentrations in the rat by Koch, Susanne, Perry, Kenneth W., Bymaster, Frank P.

“…Clinical studies of patients with treatment-resistant depression have shown that combined treatment with fluoxetine and olanzapine rapidly and significantly…”
Get full text

The mGlu2/3 receptor agonist, LY354740, blocks immobilization‐induced increases in noradrenaline and dopamine release in the rat medial prefrontal cortex by Swanson, Chad J., Perry, Kenneth W., Schoepp, Darryle D.

“…The metabotropic glutamate (mGlu2/3) receptor agonist, LY354740, exhibits anxiolytic‐like properties in a number of rodent models. The present study utilized…”
Get full text

Case history: the discovery of fluoxetine hydrochloride (Prozac) by Wong, David T, Perry, Kenneth W, Bymaster, Frank P

“…In the early 1970s, evidence of the role of serotonin (5-hydroxytryptamine or 5-HT) in depression began to emerge and the hypothesis that enhancing 5-HT…”
Get full text

Olanzapine: a basic science update by Bymaster, F, Perry, K W, Nelson, D L, Wong, D T, Rasmussen, K, Moore, N A, Calligaro, D O

“…Olanzapine, an atypical antipsychotic, has a broad receptor binding profile, which may account for its pharmacological effects in schizophrenia. In vitro…”
Get more information

A Novel, Orally Bioavailable Nociceptin Receptor Antagonist, LY2940094, Reduces Ethanol Self-Administration and Ethanol Seeking in Animal Models by Rorick-Kehn, Linda M., Ciccocioppo, Roberto, Wong, Conrad J., Witkin, Jeffrey M., Martinez-Grau, Maria A., Stopponi, Serena, Adams, Benjamin L., Katner, Jason S., Perry, Kenneth W., Toledo, Miguel A., Diaz, Nuria, Lafuente, Celia, Jiménez, Alma, Benito, Ana, Pedregal, Concepción, Weiss, Friedbert, Statnick, Michael A.

“…Background The nociceptin/orphanin‐FQ (or opioid receptor‐like [ORL1]) receptor (NOP) is localized in the mesolimbic reward pathway and has been suggested to…”
Get full text

Atomoxetine Increases Extracellular Levels of Norepinephrine and Dopamine in Prefrontal Cortex of Rat: A Potential Mechanism for Efficacy in Attention Deficit/Hyperactivity Disorder by Bymaster, Frank P, Katner, Jason S, Nelson, David L, Hemrick-Luecke, Susan K, Threlkeld, Penny G, Heiligenstein, John H, Morin, S.Michelle, Gehlert, Donald R, Perry, Kenneth W

“…The selective norepinephrine (NE) transporter inhibitor atomoxetine (formerly called tomoxetine or LY139603) has been shown to alleviate symptoms in Attention…”
Get full text

N-(4-((2-(trifluoromethyl)-3-hydroxy-4-(isobutyryl)phenoxy)methyl)benzyl)-1-methyl-1H-imidazole-4-carboxamide (THIIC), a novel metabotropic glutamate 2 potentiator with potential anxiolytic/antidepressant properties: in vivo profiling suggests a link between behavioral and central nervous system neurochemical changes by Fell, Matthew J, Witkin, Jeffrey M, Falcone, Julie F, Katner, Jason S, Perry, Kenneth W, Hart, John, Rorick-Kehn, Linda, Overshiner, Carl D, Rasmussen, Kurt, Chaney, Stephen F, Benvenga, Mark J, Li, Xia, Marlow, Deanna L, Thompson, Linda K, Luecke, Susan K, Wafford, Keith A, Seidel, Wesley F, Edgar, Dale M, Quets, Anne T, Felder, Christian C, Wang, XuShan, Heinz, Beverly A, Nikolayev, Alexander, Kuo, Ming-Shang, Mayhugh, Daniel, Khilevich, Albert, Zhang, Deyi, Ebert, Philip J, Eckstein, James A, Ackermann, Bradley L, Swanson, Steven P, Catlow, John T, Dean, Robert A, Jackson, Kimberley, Tauscher-Wisniewski, Sitra, Marek, Gerard J, Schkeryantz, Jeffrey M, Svensson, Kjell A

“…The normalization of excessive glutamatergic neurotransmission through the activation of metabotropic glutamate 2 (mGlu2) receptors may have therapeutic…”
Get more information

Fluoxetine, but not other selective serotonin uptake inhibitors, increases norepinephrine and dopamine extracellular levels in prefrontal cortex by BYMASTER, Frank P, WEI ZHANG, CARTER, Petra A, SHAW, Janice, CHERNET, Eyassu, PHEBUS, Lee, WONG, David T, PERRY, Kenneth W

“…The selective serotonin uptake inhibitor (SSRI) fluoxetine has been shown to not only increase the extracellular concentrations of serotonin, but also dopamine…”
Get full text

M4 muscarinic receptors regulate the dynamics of cholinergic and dopaminergic neurotransmission: relevance to the pathophysiology and treatment of related CNS pathologies by Tzavara, Eleni T, Bymaster, Frank P, Davis, Richard J, Wade, Mark R, Perry, Kenneth W, Wess, Jurgen, McKinzie, David L, Felder, Chris, Nomikos, George G

“…Dopaminergic dysfunction is an important pathogenetic factor for brain pathologies such as Parkinson's disease, ADHD, schizophrenia, and addiction as well as…”
Get full text